FACE-OFF: Low-Risk MDS SOHO 2025
Panelists discuss how to optimize treatment approaches for patients with lower-risk myelodysplastic syndrome through a competitive debate format covering luspatercept vs erythropoiesis-stimulating agents as first-line therapy, management of super-responders, timing of treatment initiation, and real-world evidence from recent clinical trials including COMMANDS, MEDALIST, and IMerge.
EP. 1: Long-Term Update on Efficacy and Safety in Phase 3 COMMANDS Trial
September 22nd 2025Panelists discuss how the COMMANDS phase 3 trial data demonstrate long-term efficacy and safety benefits of a newer drug compared with ESA in patients with low-risk myelodysplastic syndromes (MDS), with improved 5-year overall survival rates (54% vs 42%) and sustained transfusion independence lasting over 6 months, while maintaining a well-tolerated safety profile with no new safety signals identified in extended follow-up.
EP. 2: Expert Perspectives on Long-Term COMMANDS Findings
September 22nd 2025Panelists discuss how the long-term COMMANDS data reveal impressive survival benefits and durable transfusion independence responses, particularly in patients with SF3B1 mutations, while debating whether the observed survival advantage stems from transfusion independence alone or represents true disease modification through broader systemic effects beyond just bone marrow changes.
